Skip to main content
LAVA Therapeutics NV logo

LAVA Therapeutics NV — Investor Relations & Filings

Ticker · LVTX ISIN · NL0015000AG6 LEI · 724500HENIO3AVE6KA30 US Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2021-03-18 Regulatory Filings
Country NL Netherlands
Listing US LVTX

About LAVA Therapeutics NV

https://www.lavatherapeutics.com/

LAVA Therapeutics NV is a clinical-stage immuno-oncology company that develops cancer therapies through its proprietary Gammabody® platform. This platform generates bispecific antibodies designed to engage and activate Vγ9Vδ2 (Vgamma9 Vdelta2) T cells, a unique and abundant subset of immune effector cells. The therapeutic approach aims to direct these T cells to tumors, leading to the selective killing of cancer cells and the stimulation of a broader, durable anti-tumor immune response. The company's focus is on creating treatments that complement natural tumor recognition and have the potential to enhance patient survival across various malignancies.

Recent filings

Filing Released Lang Actions
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is a regulatory filing related to the registration of common shares on the Nasdaq Stock Market. The document does not contain financial statements, earnings data, or management discussion, but rather is a formal registration statement. The length is 3659 characters, which is relatively short and consistent with a regulatory filing. Therefore, this document fits best under the category of Regulatory Filings (RNS).
2021-03-18 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form F-1 filed by LAVA Therapeutics B.V. The letter addresses specific comments on disclosures and amendments to the Registration Statement. It is not the Registration Statement itself, nor does it contain financial statements or substantive financial data. The document is a regulatory correspondence related to a filing, serving as a response to SEC comments. The document length is under 5,000 characters and it is a letter responding to regulatory comments, which fits the category of Regulatory Filings (RNS) rather than the actual Registration Statement or any other report type.
2021-03-18 English
F-1/A
Regulatory Filings Classification · 95% confidence The document is a Form F-1/A, which is an amendment to a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is related to an initial public offering (IPO) of common shares by LAVA Therapeutics B.V., including detailed information such as the offering price, underwriting details, risk factors, financial statements, management discussion, and corporate reorganization. The document is a registration statement prospectus, which is a regulatory filing used to register securities for public offering. This type of document does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update, but is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and compliance document related to securities registration. The document length is substantial (15,000 characters), and it contains detailed information typical of an SEC registration statement amendment, not just an announcement or a brief notice. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-03-18 English
Regulatory Filings 2021
Regulatory Filings
2021-03-10 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed letter addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form F-1 for LAVA Therapeutics B.V. It discusses confidential treatment requests, preliminary IPO price range, historical determinations of fair value of common shares, and valuation methodologies used for the company's shares. The content is focused on IPO registration and valuation details rather than financial results, management changes, or shareholder votes. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a regulatory filing related to the IPO registration process, specifically a supplemental letter accompanying a Form F-1 registration statement. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-03-10 English
Regulatory Filings 2021
Regulatory Filings
2021-03-03 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.